Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB)

Clinical Breast Cancer

Volumn 8, Issue 1, 2008, Pages 97-100

  Frassoldati, Antonio ^a   Guarneri, Valentina ^a   Piacentini, Federico ^a   Jovic, Gordana ^a   Giovannelli, Simona ^a   Oliva, Cristina ^b   Conte, Pier Franco ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Mitogen activated protein kinase; Multigated acquisition scan; Tyrosine kinase inhibitor

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PLACEBO;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; HUMAN; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

EID: 40449112910     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.010     Document Type: Article

References (25)

1. S Massarweh R Schiff Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr Relat Cancer 13 suppl 1 2006 s15 s24
2. R Schiff SA Massarweh J Shou Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators Cancer Chemother Pharmacol 56 suppl 1 2005 10 20
3. S Massarweh CK Osborne S Jiang Mechanisms of tumour regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor–positive, HER-2/ neu -positive breast cancer Cancer Res 66 2006 8266 8273
4. RJ Pietras J Arboleda DM Reese HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 1995 2435 2446
5. CK Osborne R Schiff Estrogen-receptor biology: continuing progress and therapeutic implications J Clin Oncol 23 2005 1616 1622
6. CK Osborne V Bardou TA Hopp Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer J Natl Cancer Inst 95 2003 353 361
7. Y-L Chung M-L Sheu S-C Yang Resistance to tamoxifeninduced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer Int J Cancer 97 2002 306 312
8. I Nemere RJ Pietras PF Blackmore Membrane receptors for steroid hormones: signal transduction and physiological significance J Cell Biochem 88 2003 438 445
9. RJ Santen RX Song Z Zhang Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity Endocr Relat Cancer 12 suppl 1 2005 s61 s73
10. IR Hutcheson JM Knowlden T-A Madden Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifenresistant MCF-7 cells Breast Cancer Res Treat 81 2003 81 93
11. MC Gutierrez S Detre S Johnston Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase J Clin Oncol 23 2005 2469 2476
12. G Arpino H Weiss A Wakeling Complete disappearance of ERC/HER2C breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition Breat Cancer Res Treat 88 suppl 1 2004 s15 (Abstract 23).
13. G Arpino H Weiss AV Lee Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance J Natl Cancer Inst 97 2005 1254 1261
14. MJ Ellis A Coop B Singh Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1–and/or ErbB-2–positive, estrogen receptor–positive primary breast cancer: evidence from a phase III randomized trial J Clin Oncol 19 2001 3808 3816
15. G Viale MM Regan E Maiorano Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 J Clin Oncol 25 2007 3846 3852
16. M Dowsett C Allred J Knox Relationship between quantitative estrogen and progesterone receptor expression and human epidemal growth factor receptor (HER-2) status with recurrence in the Armidex, Tamoxifen, Alone or in Combination Trial J Clin Oncol 2008 [e-pub ahead of print].
17. W Eiermann S Paepke J Appfelstaedt Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study Ann Oncol 12 2001 1527 1532
18. IE Smith M Dowsett SR Ebbs Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicentre double-blind randomized trial J Clin Oncol 23 2005 5108 5116
19. A Polychronis HD Sinnett D Hadjiminas Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factorreceptor-positive primary breast cancer: a double-blind placebocontrolled phase II randomised trial Lancet Oncol 6 2005 383 391
20. JF Robertson E Gutteridge KL Cheung Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor (ER)-positive and ER negative breast cancer: results from a phase II study Proc Am Soc Clin Oncol 22 2003 7 (Abstract 23).
21. JR Mackey B Kaufman M Clemens Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast Cancer Breast Cancer Res Treat 100 suppl 1 2006 s5 (Abstract 3).
22. W Xia RJ Mullin BR Keith Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erB2 and downstream Erk1/2 and AKT pathways Oncogene 21 2002 6255 6263
23. I Chu K Blackwell S Chen The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 2005 18 25
24. VF Semiglazov VG Ivanov VV Semiglazov Neoadjuvant endocrine therapy vs chemotherapy for postmenopausal ER-positive breast cancer patients Breast Cancer Res Treat 88 suppl 1 2004 s106 (Abstract 2090).
25. SR Johnston J Head S Pancholi Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer Clin Cancer Res 9 2003 524s 532s